Resources & Reports

Newsletter

Anticipation Builds for Expected DEA Controlled Substance Rule, Definitive End to PHE, and much more!

CCHP’s February Newsletter is here! This month’s topics include – Study Finds COVID Flexibilities did NOT Impact Buprenorphine Overdoses & Potential for New Permanent Controlled Substance Prescribing Rule; Biden Administration Announces End of PHE May 11, 2023; AMA CPT Editorial Panel Agenda Includes New Office Visit Telemedicine Codes; Developments in CCHP’s Telehealth Policy Finder and Policy Trends Map; Telehealth Indicator Integrated into CMS Online Healthcare Provider Compare Tool; CMS Proposes Telehealth Focused Digital Health Education Requirements for Medicare Advantage Organizations; HHS Proposes Standards for Electronic Signatures; CMS COVID-19 Flexibility Transmittal for FQHC/RHCs Updated with New Distant Site Payment Amount; Abortion Cases Filed Challenging State Abortion Restrictions; Medicare Telehealth Trends Data Updated through June 2022; KFF Medicaid Behavioral Health Telehealth Survey Results; FQHC Billing Assistance.

< BACK TO NEWSLETTER